Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
PR Newswire•05/10/2026•07:50 ET
0
Key Highlights
- ➤Lilly will present 21 dermatology posters at Fall Clinical 2026
- ➤EBGLYSS data highlight durable control and every-eight-week maintenance dosing
- ➤EBGLYSS pediatric findings cover patients as young as six months
- ➤Taltz plus Zepbound analyses examine immunometabolic outcomes in psoriasis and obesity
- ➤Olumiant data show long-term pediatric efficacy and safety in severe alopecia areata
Expert Statements
Adrienne Brown, Executive vice president and president, Lilly Immunology
“For people living with chronic skin conditions, such as atopic dermatitis and psoriasis, the burden can be constant—relentless itch and significant pain that get in the way of daily routines”
Adrienne Brown, Executive vice president and president, Lilly Immunology
“The breadth of dermatologic data we’re presenting at Fall Clinical highlights our continued focus on addressing the needs of people living with immune and inflammatory conditions and advancing outcomes that matter most to them.”
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions PR Newswire
Latest EBGLYSS (lebrikizumab-lbkz) data reinforce durable disease control, less frequent maintenance dosing and reduced topical treatment use in patients with moderate-to-severe atopic dermatitis
Get started
Create a free account to read the full story.